Spyre Therapeutics (STU:3920) Cyclically Adjusted Book per Share: €50.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3920 Spyre Therapeutics Inc STU:3920
26 GF Score
Price €79.50
! 3 Warning Signs
View Full Analysis

What is Spyre Therapeutics Cyclically Adjusted Book per Share?

Spyre Therapeutics STU:3920 +1.92% 26 Cyclically Adjusted Book per Share is €50.54 as of Jun. 2026. GuruFocus rates STU:3920 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Spyre Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €9.482. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €50.54 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Spyre Therapeutics's average Cyclically Adjusted Book Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-09-17), Spyre Therapeutics's current stock price is €79.50. Spyre Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €50.54. Spyre Therapeutics's Cyclically Adjusted PB Ratio of today is 1.57.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Spyre Therapeutics was 2.06. The lowest was 0.18. And the median was 0.52.


Spyre Therapeutics  (STU:3920) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Spyre Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=79.50/50.544
=1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Spyre Therapeutics was 2.06. The lowest was 0.18. And the median was 0.52.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Spyre Therapeutics Cyclically Adjusted Book per Share Related Terms


Spyre Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Cyclically Adjusted Book per Share Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 40.77 44.86 51.79

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.51 50.05 51.37 53.99 50.54

STU:3920 vs TGTX, IMVT, IBRX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:3920
26GF Score
Spyre Therapeutics Inc STU:3920
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spyre Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.482/333.9520*333.9520
=9.482

Current CPI (Jun. 2026) = 333.9520.

Spyre Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 112.959 241.428 156.249
201612 111.120 241.432 153.703
201703 99.360 243.801 136.101
201706 83.407 244.955 113.710
201709 71.258 246.819 96.414
201712 62.866 246.524 85.161
201803 53.112 249.554 71.074
201806 71.785 251.989 95.134
201809 62.026 252.439 82.054
201812 61.085 251.233 81.197
201903 89.785 254.202 117.953
201906 75.805 256.143 98.832
201909 63.265 256.759 82.285
201912 46.008 256.974 59.790
202003 33.460 258.115 43.291
202006 75.989 257.797 98.437
202009 65.006 260.280 83.406
202012 59.574 260.474 76.379
202103 53.701 264.877 67.705
202106 51.180 271.696 62.907
202109 44.660 274.310 54.370
202112 37.389 278.802 44.785
202203 28.033 287.504 32.562
202206 32.898 296.311 37.077
202209 28.027 296.808 31.534
202212 18.032 296.797 20.289
202303 11.841 301.836 13.101
202306 -58.663 305.109 -64.209
202309 -57.249 307.789 -62.115
202312 -0.023 306.746 -0.025
202403 -0.826 312.332 -0.883
202406 4.016 314.175 4.269
202409 2.991 315.301 3.168
202412 5.801 315.605 6.138
202503 5.019 319.799 5.241
202506 6.393 322.561 6.619
202509 6.367 324.800 6.546
202512 6.092 324.054 6.278
202603 5.669 330.213 5.733
202606 9.482 333.952 9.482

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €50.54 mean?
Spyre Therapeutics (STU:3920) has a Cyclically Adjusted Book per Share of €50.54 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Cyclically Adjusted Book per Share too high?
Spyre Therapeutics' current Cyclically Adjusted Book per Share is €50.54. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Cyclically Adjusted Book per Share compare to TGTX and IMVT?
Spyre Therapeutics' Cyclically Adjusted Book per Share of €50.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Cyclically Adjusted Book per Share is €50.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (STU:3920) has a current Cyclically Adjusted Book per Share of €50.54. The current Cyclically Adjusted Book per Share is €50.54. Spyre Therapeutics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Spyre Therapeutics (STU:3920), the current Cyclically Adjusted Book per Share is €50.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score

Get the complete analysis for STU:3920

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€79.50
Price